Invitrogen™ SARS-CoV-2 Spike Protein S1/S2 (BA.2.12.1) His-tag, trimer Recombinant Protein

Descripción

It is recommended that the protein be aliquoted for optimal storage. It is recommended that sterile water (400 uL) be added to the vial to prepare a stock solution of 0.25 mg/mL. Concentration is measured by UV. SARS-CoV-2 spike S1/S2 (Accession # YP_009724390.1) with T19I, L24S, del25-27, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, S704L, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P substitutions and furin cleavage site mutations expressed with the bacteriophage T4 fibritin and a C-terminal His-tag. The mutations were identified in the SARS-CoV-2 varient known as BA.2.12.1.

It has recently been shown that SARS (severe acute respiratory syndrome) is caused by a human coronavirus. Human coronaviruses are the major cause of upper respiratory tract illness, such as the common cold, in humans. Coronaviruses are positive-stranded RNA viruses, featuring the largest viral RNA genomes known to date (27-31 kb). The first step in coronavirus infection is binding of the viral spike protein, a 139-kDa protein, to certain receptors on host cells. The spike protein is the main surface antigen of the coronavirus. The glycosylated spike protein (as well as the nucleocapsid protein) can be detected in infected cell culture supernatants with antisera from SARS patients.